Kristina Drott

affiliated with the university

Research areas and keywords

UKÄ subject classification

  • Cancer and Oncology


  • B-cell lymphoma , Epigenetics, HDAC inhibitor


Many B-cell lymphomas are characterised by mutations in epigenetic regulators, either at primary diagnosis or at disease relapse. Therefore, both development and treatment resitance of B-cell lymphomas, are probably dependent on correct epigenetic regulation of chromatin conformation and gene expression. Starting from the overall hypothesis that a deranged epigenetic regulation can be restored by treatment with epigenetic modulators like histone deacetylase inhibitors (HDACis) and DNA methyltransferase inhibitors, the research in our group focuses on epigenetic regulation of gene expression in B-cell lymphomas,We aim to increase sensitivity to treatment with chemo- and immuno-therapy by epigenetic manipulation. We are presently evaluating the response of the HDACi Valproate in diffuse large Bcell lymphoma patients (the VALFRID trial) and in patients with chronic lymphocytic leukemia (the PREVAIL trial). Simultaneously, we are elaborating our findings in lymphoma cell lines and primary cells, where we have the opportunity to study the function of individual epigenetic regulators in detail. We utilize techniques like chromatin immunoprecipitation (ChIP), flow cytometry, gene knockdown by lentiviral transduction of shRNA, qPCR and Western blot. Since a range of HDACis and DNA methyltransferase inhibitors are presently clinically utilised, we hope that our findings will soon be of patient benefit.

Highlighted research outputs

Ageberg, M., Fjordén, K., Relander, T. & Kristina Drott, 2013, In : American Journal of Translational Research. 5, 2, p. 170-183

Research output: Contribution to journalArticle

Ageberg, M., Fjordén, K., Lindén, O., Linderoth, J., Mats Jerkeman & Kristina Drott, 2011, In : Experimental Cell Research. 317, p. 1179-1191

Research output: Contribution to journalArticle

View all (17)